The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
Endocytosis and Cancer
Open accessAbstract
Endocytosis entails selective packaging of cell-surface proteins, such as receptors for cytokines and adhesion components, in cytoplasmic vesicles (endosomes).The series of sorting events that determines the fate of internalized proteins, either degradation in lysosomes or recycling back to the plasma membrane, relies on intrinsic sequence motifs, posttranslational modifications (e.g., phosphorylation and ubiquitination), and transient assemblies of both Rab GTPases and phosphoinositide-binding proteins.This multicomponent process is enhanced and skewed in cancer cells; we review mechanisms enabling both major drivers of cancer, p53 and Ras, to bias recycling of integrins and receptor tyrosine kinases (RTKs).Likewise, cadherins and other junctional proteins of cancer cells are constantly removed from the cell surface, thereby disrupting tissue polarity and instigating motile phenotypes.Mutant forms of RTKs able to evade Cbl-mediated ubiquitination, along with overexpression of the wild-type forms and a variety of defective feedback regulatory loops, are frequently detected in tumors.Finally, we describe pharmacological attempts to harness the peculiar endocytic system of cancer, in favor of effective patient treatment.C ancer cells are fundamentally similar to their normal counterparts.Their differences lie in a series of relatively subtle modifications of normal physiological processes that, when combined, can create markedly altered phenotypes and behaviors.It has long been suspected that endocytosis is one such physiological process that is modified in cancer.Not only do cancer cells show alterations in the overall appearance and dynamics of the plasma membrane, but also the common inability of cancer cells to properly regulate the function of several types of receptors, including many RTKs, strongly suggests an inability to internalize, recycle, or degrade these key cancer drivers.In recent years, there has been considerable progress made toward under-standing the breadth and mechanisms of alterations to the endocytic pathway that occur during cancer.Although our knowledge remains incomplete and the pathophysiological contributions of these alterations may not be wholly understood, this review considers just how profoundly the pathways of endocytosis can be modified in cancer and what this reveals about disease mechanisms and normal processes. Organization of the Endocytic PathwayAlthough the basic features of the endocytic pathway in animal cells were established more than two decades ago (Mellman 1996a), subsequent years have witnessed the accumulation of
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · cited 2×
“Approximately 10% to 30% of tumors from patients with non-small-cell lung cancer (NSCLC) harbor somatic activating mutations in the gene encoding EGFR (Lynch et al. 2004; Paez et al. 2004; Pao et al. 2004).”
BackgroundThe basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Cited by
Emerging functions of the EGFR in cancer
Sigismund, S., Avanzato, D., & Lanzetti, L. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12155 · Cited by 1,469
Endocytosis: a pivotal pathway for regulating metastasis
Khan, I., & Steeg, P. S. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01179-8 · Cited by 178
Endosomal trafficking in metabolic homeostasis and diseases
Gilleron, J., & Zeigerer, A. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00737-9 · Cited by 57
Fariha, F. T. J., Fuad, M., Saha, C. S., Hossen, S., & Hossain, M. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-13315-6 · Cited by 1
Metadata
- Authors
- Mellman, I., & Yarden, Y.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2013-12-01
- Volume
- 5
- Issue
- 12
- Pages
- a016949-a016949
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2068322045
- Cited by
- 394
- References
- 171
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endocytosis and Cancer. https://app.cochat.ai/papers/10.1101/cshperspect.a016949
- The paper
- Mellman, I., & Yarden, Y. (2013). Endocytosis and Cancer. Cold Spring Harbor Perspectives in Biology. https://doi.org/10.1101/cshperspect.a016949
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.